All In Biotech

Drug Trial Radar · NCT04484025

SPI-1005 Treatment in Moderate COVID-19 Patients

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 Patients

Last checked: Nov 19, 2026Latest source record: Oct 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

60

Planned (sponsor's estimate)

Start

Oct 12, 2021

Primary completion

Dec 31, 2023

Study completion Dec 31, 2023

Sponsor

Sponsor type
Industry
First posted
Jul 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a randomized, double-blind, placebo-controlled, dose escalation, multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and moderate symptoms of COVID-19 disease.

Conditions

  • Covid19
  • Corona Virus Infection
  • Coronavirus
  • Coronavirus Infection

Interventions

  • EbselenDrug

    Glutathione peroxidase mimetic

  • PlaceboDrug

    Matching placebo containing excipients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse eventsTime frame: 30 days

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Yale University

    New Haven, Connecticut

  • St. Luke's Cystic Fibrosis Center of Idaho

    Boise, Idaho

  • Kansas University Medical Center

    Kansas City, Kansas

  • Washington University in St. Louis

    St Louis, Missouri

  • Duke University

    Durham, North Carolina

  • Wake Forest University

    Winston-Salem, North Carolina

  • University of Texas Southwestern

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.